IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

80000

š

Attorney

Docket: 32379

IAP2 Rec'd PCT/PTO 29 SEP 2006

Group Art Unit: Not yet Assigned

In re Applicant:

Francesca LEVI-SCHAFFER et al

National Phase of PCT/ IL2005/000358 Serial No.:

Herewith Filed:

For:

Bi-Specific Complexes For Targeting Cells Involved In Allergic-Type Reactions,

Compositions And Uses Thereof

Not yet Assigned Examiner:

Mail Stop Amendment Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

> Respectfully submitted, Martin Q. Maguika

Martin D. Moynihan Registration No. 40,338

Dated: September 14, 2006

10/594926

IAP2 Rec'd PCT/PTO 29 SEP 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ction of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to respond to a colle

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

nd	to a collection of information un.	less it contains a valid ONE conduct manner			
Ť		Complete if Known			
t	Application Number	National Phase of PCT/ IL2005/000358			
ŀ	Filing Date	Herewith			
ł	First Named Inventor	Francesca LEVI-SCHAFFER et al			
ł	Art Unit	Not Yet Available			
١	Examiner Name	Not Yet Available			
_	Attorney Docket Number	32379			
	Attorney Docket Homes	1			

Sheet	1	1	of	2			ey Docket Number		
					U.S. PAT Publication Da	ENT D	OCUMENTS Name of	Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Examiner Initials*	Cite No. 1		nt Number	\dashv	MM-DD-YYY	Ÿ	Applicant of C	Cited Document	Figures Appear
		Number-Kit	nd Code ^{2 (if los}	PRD)					
									+
				\rightarrow					
	-								
	_								
	-								
	-								
	1								
	+-	-					ļ		

		FOREIGN	PATENT DOC			Pages, Columns, Lines,	Т
Examiner Initials*	Cite No. 1	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Where Relevant Passages or Relevant Figures Appear	
		Country Code ⁵ Number ⁴ Kind Code ⁵ (if known)	04-17-2003	Bigler et a	d		⊦
	2	PCT WO 03/030835 PCT WO 03/064662	08-7-2003	Thomas et	al.		+
	_						Ţ
							+
					Date	1	
Examiner					Considered		_

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. *Applicants arique clatton designation number (options). *Deal Crists Codes considered, include copy of copy of this form with next communication to applicant. *Applicants arique clatton designation number (options). *Deal Crists Codes considered, include copy of copy of this form with next communication to the communication of the volution code (WIPO Stances ST 3).

Of USPTO Patent Documents at <u>Victor Visions Codes. *Experiments of the Codes </u> by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including adhering, presping, and submen, the completed application from to the USPTO. Time will vary depending upon the individual cardy comments on the amount of time you require to comment of the completed application from to the USPTO. Time will vary depending upon the individual cardy comments on the amount of time you require to comments. P.O. 80x 1450, Alexandria, VA 2213-1450, DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS.

US. Departments of the Parks of DO Brackets Alexandria, VA 2213-1450. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

10/594926

IAP2 Rec'd PCT/PTO 29 SEP 2006

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. National Phase of PCT/ IL2005/000358 . • Substitute for form 1449A/PTO Application Number Herewith Filing Date INFORMATION DISCLOSURE Francesca LEVI-SCHAFFER et al First Named Inventor Not Yet Available STATEMENT BY APPLICANT Group Art Unit Not Yet Available Examiner Name (use as many sheets as necessary) Attorney Docket Number 32379 Of OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Sheet include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T2 Cite Examiner publisher, city and/or country where published. Initials No. Ott et al. "Activating and Inhibitory Signaling in Mast Cells: New Opportunities for Therapeutic Intervention?", Journal of Allergy and Clinical Immunology, 106: 429-440, 2000. Biassoni et al. "Human Natural Killer Cell Receptors: Insights Into Their Molecular Function and Structure", Journal of Cellular and Molecular Medicine, 7(4): 376-387, Cantoni et al. "Molecular and Functional Characterization of IRp60, A Member of the Immunoglobulin Superfamily That Functions as An Inhibitory Receptor in Human NK Cells", European Journal of Immunology, 29: 3148-3159, 1999. Bachelet et al. "The inhibitory Receptor IRp60 (CD300a) Is Expressed and Functional on Human Mast Cells", The Journal of Immunology, 175: 7989-7995, Munitz et al. "The inhibitory Receptor IRp60 (CD300a) Suppresses the Effects of IL-5, GM-CSF and Eotaxin on Human Peripheral Blood Eosinophils", Blood, 1st Ed. 7 Paper, Prepublished Online, P.1-40, 2005. Levi-Schaffer et al. "LgE Activation of Mast Cells: The Beginning of the End or the 8

End of the Beginning?", Lecture Abstracts, 2005.

of Allergy and Clinical Immunology, S206, 2005. Abstract.

١					
Ī			 		
·			 		
ſ	т			C Hered	
١		 		Considered	
١	Signature	 			

Bachelet et al. "IRp60 Modulates An array of Human Mast Cell Functions", Journal

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not Considered, include copy of this form with next communication to applicant or produce claims of the communication of applicant or produced claims designed calculated expect of this form with next communication to applicant or produced claims designed calculated resigned control of the communication of applicant or produced claims designed control or produced to the communication of th

Applicant's urique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retains benefit by the public is to file (and by the TUSPTO is process) an application. Confidentiality is operated by 3.5 U.S. C. 1.22 and 37 CPR 1.14. the collection is estimated to take 2 hours to complete, including a supplication. Confidentiality is operated by 3.5 U.S. C. 1.22 and 37 CPR 1.14. the collection is estimated to take 2 hours to complete, including a supplication. Confidentiality is operated by 5.0 U.S. C. 1.22 and 37 CPR 1.14. the collection is estimated to take 2 hours to complete, including a supplication form to the USPTO. Time will vary depending upon the individual case. When complete the time of the consideration from a reference of the hourse. The hourse is the hourse of the consideration from a reference of the hourse. The hourse is the hourse of the hourse of the hourse of the hourse. guinering, preparing, and submitting the completed application form to the USH1O. Lime will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patient and Trademark Office, U. S. Department of commence, P.O. Box 1450, Nearonfax, V. A. 22313-1450. D. NOT SEND TEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, V. A. 22313-1450.